Wall Street analysts expect that Urovant Sciences Ltd (NASDAQ:UROV) will announce earnings of ($0.96) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Urovant Sciences’ earnings. The highest EPS estimate is ($0.86) and the lowest is ($1.08). Urovant Sciences posted earnings of ($0.87) per share in the same quarter last year, which suggests a negative year over year growth rate of 10.3%. The business is scheduled to announce its next earnings report on Wednesday, February 12th.
According to Zacks, analysts expect that Urovant Sciences will report full-year earnings of ($4.05) per share for the current fiscal year, with EPS estimates ranging from ($4.38) to ($3.63). For the next fiscal year, analysts anticipate that the firm will report earnings of ($4.27) per share, with EPS estimates ranging from ($5.39) to ($3.62). Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Urovant Sciences.
Urovant Sciences (NASDAQ:UROV) last issued its quarterly earnings results on Tuesday, November 5th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.30.
UROV has been the subject of a number of research reports. ValuEngine lowered shares of Urovant Sciences from a “hold” rating to a “sell” rating in a report on Monday, December 16th. HC Wainwright raised their price target on shares of Urovant Sciences from $28.00 to $33.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Finally, Zacks Investment Research lowered shares of Urovant Sciences from a “hold” rating to a “sell” rating in a report on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating and three have assigned a buy rating to the company. Urovant Sciences currently has an average rating of “Hold” and a consensus target price of $22.69.
Shares of Urovant Sciences stock opened at $14.39 on Friday. The company has a debt-to-equity ratio of 1.83, a current ratio of 6.65 and a quick ratio of 6.65. The firm has a market cap of $478.51 million, a P/E ratio of -3.25 and a beta of 1.97. The firm has a 50 day simple moving average of $12.84 and a 200 day simple moving average of $9.88. Urovant Sciences has a fifty-two week low of $6.45 and a fifty-two week high of $15.98.
Institutional investors have recently modified their holdings of the stock. Marshall Wace North America L.P. acquired a new stake in shares of Urovant Sciences in the first quarter valued at approximately $49,000. Northern Trust Corp increased its holdings in shares of Urovant Sciences by 55.8% in the second quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock valued at $136,000 after purchasing an additional 6,144 shares in the last quarter. First Trust Advisors LP acquired a new stake in shares of Urovant Sciences in the third quarter valued at approximately $163,000. Marshall Wace LLP acquired a new stake in shares of Urovant Sciences in the first quarter valued at approximately $325,000. Finally, LVW Advisors LLC acquired a new stake in shares of Urovant Sciences in the third quarter valued at approximately $372,000. 22.37% of the stock is owned by institutional investors and hedge funds.
About Urovant Sciences
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.
Featured Story: What sectors are represented in the Nikkei Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.